XMS.F XTANT MEDICAL HLDGS
- Market cap
- EUR 33.9M
- P/E
- -
- P/B
- 0.95x
- ROE
- -62.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is XMS.F undervalued?
Graham numberThe Graham number of XTANT MEDICAL HLDGS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
XTANT MEDICAL HLDGS fundamental analysis
No fundamental analysis for XTANT MEDICAL HLDGS yet.
XTANT MEDICAL HLDGS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About XTANT MEDICAL HLDGS
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes oste…
Full company profileXTANT MEDICAL HLDGS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
XTANT MEDICAL HLDGS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 55.3M | 58.0M | 91.3M | 117M | 134M | 87.8M |
| Gross Profit | 32.5M | 32.1M | 55.5M | 68.2M | 84.3M | 50.6M |
| Operating Income | -3.85M | -6.76M | -10.2M | -12.1M | 7.28M | -14.2M |
| EBITDA | - | -5.43M | 5.08M | -7.88M | 15.9M | -20.4M |
| Net Income | -4.85M | -8.49M | 660K | -16.4M | 4.97M | -25.0M |
| EPS | -0.06 | -0.08 | 0.01 | -0.12 | 0.04 | -0.18 |
| Balance Sheet | ||||||
| Total Assets | 54.7M | 60.2M | 92.6M | 93.8M | 94.1M | 79.7M |
| Total Liabilities | 23.8M | 26.1M | 41.3M | 50.9M | 43.2M | 39.7M |
| Shareholders' Equity | 30.9M | 34.2M | 51.3M | 43.0M | 51.0M | 40.0M |
| Cash & Short-term Investments | 18.2M | 20.3M | 5.72M | 6.20M | 17.1M | 9.87M |
| Cash Flow | ||||||
| Operating Cash Flow | 439K | -5.34M | -9.52M | -11.9M | 12.5M | -18.8M |
| Capital Expenditure | 2.12M | 1.76M | 1.46M | 4.11M | 2.38M | 882K |
| Free Cash Flow | -1.68M | -7.11M | -11.0M | -16.0M | 10.2M | -19.7M |
| Ratios | ||||||
| ROE | -15.7% | -24.8% | 1.3% | -38.3% | 9.8% | -62.5% |
| ROA | -8.9% | -14.1% | 0.7% | -17.5% | 5.3% | -31.4% |
| Net Profit Margin | -8.8% | -14.6% | 0.7% | -14.0% | 3.7% | -28.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
XTANT MEDICAL HLDGS dividends
XTANT MEDICAL HLDGS has not paid dividends in the last 6 fiscal years.
Who owns XTANT MEDICAL HLDGS
- Insiders 15.65%
- Institutions 56.96%
- Public & others 27.39%
- Shares outstanding 140M
- Free float 54.2M
XTANT MEDICAL HLDGS company profile
- Company name
- XTANT MEDICAL HLDGS
- Ticker
- XMS.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 151
- Fiscal year end
- December
- Address
- 664 Cruiser Lane, Belgrade, MT, United States, 59714
- Phone
- 406 388 0480
- Website
- xtantmedical.com
About XTANT MEDICAL HLDGS
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.
XTANT MEDICAL HLDGS management
4- Mr. Sean E. BrownePresident, CEO & Director · born 1966
- Mr. Scott C. NeilsChief Financial Officer · born 1985
- Mr. Mark A. SchallenbergerChief Operations Officer · born 1987
- Ms. Catherine LundyVice President of Human Resources